Department of Medicine, Division of Cardiology, University of Colorado Denver, Aurora, Colorado, USA.
Department of Pediatrics, Division of Pulmonary and Critical Care Medicine, University of Colorado Denver, Aurora, Colorado, USA.
Pulm Circ. 2015 Mar;5(1):63-72. doi: 10.1086/679700.
Reversible lysine acetylation has emerged as a critical mechanism for controlling the function of nucleosomal histones as well as diverse nonhistone proteins. Acetyl groups are conjugated to lysine residues in proteins by histone acetyltransferases and removed by histone deacetylases (HDACs), which are also commonly referred to as lysine deacetylases. Over the past decade, many studies have shown that HDACs play crucial roles in the control of left ventricular (LV) cardiac remodeling in response to stress. Small molecule HDAC inhibitors block pathological hypertrophy and fibrosis and improve cardiac function in various preclinical models of LV failure. Only recently have HDACs been studied in the context of right ventricular (RV) failure, which commonly occurs in patients who experience pulmonary hypertension (PH). Here, we review recent findings with HDAC inhibitors in models of PH and RV remodeling, propose next steps for this newly uncovered area of research, and highlight potential for isoform-selective HDAC inhibitors for the treatment of PH and RV failure.
可逆赖氨酸乙酰化已成为控制核小体组蛋白以及各种非组蛋白功能的关键机制。乙酰基通过组蛋白乙酰转移酶与蛋白质中的赖氨酸残基结合,并通过组蛋白脱乙酰酶(HDACs)去除,HDACs 也通常被称为赖氨酸脱乙酰酶。在过去的十年中,许多研究表明 HDACs 在控制左心室(LV)心脏对压力的重塑中起着至关重要的作用。小分子 HDAC 抑制剂可阻止病理性肥大和纤维化,并改善 LV 衰竭的各种临床前模型中的心脏功能。直到最近,HDACs 才在右心室(RV)衰竭的背景下进行了研究,而 RV 衰竭在经历肺动脉高压(PH)的患者中很常见。在这里,我们回顾了 PH 和 RV 重塑模型中 HDAC 抑制剂的最新发现,为这一新发现的研究领域提出了下一步的建议,并强调了同工型选择性 HDAC 抑制剂治疗 PH 和 RV 衰竭的潜力。